JP2003507342A5 - - Google Patents

Download PDF

Info

Publication number
JP2003507342A5
JP2003507342A5 JP2001516570A JP2001516570A JP2003507342A5 JP 2003507342 A5 JP2003507342 A5 JP 2003507342A5 JP 2001516570 A JP2001516570 A JP 2001516570A JP 2001516570 A JP2001516570 A JP 2001516570A JP 2003507342 A5 JP2003507342 A5 JP 2003507342A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
carbon
phenyl
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003507342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/021021 external-priority patent/WO2001012227A1/en
Publication of JP2003507342A publication Critical patent/JP2003507342A/ja
Publication of JP2003507342A5 publication Critical patent/JP2003507342A5/ja
Pending legal-status Critical Current

Links

JP2001516570A 1999-08-12 2000-08-02 結腸ポリープおよび直腸結腸癌の処置または抑制のためのnsaidおよびegfrキナーゼインヒビターを含有する組成物 Pending JP2003507342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
US09/373,261 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (2)

Publication Number Publication Date
JP2003507342A JP2003507342A (ja) 2003-02-25
JP2003507342A5 true JP2003507342A5 (https=) 2007-09-13

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001516570A Pending JP2003507342A (ja) 1999-08-12 2000-08-02 結腸ポリープおよび直腸結腸癌の処置または抑制のためのnsaidおよびegfrキナーゼインヒビターを含有する組成物

Country Status (24)

Country Link
EP (1) EP1202746B1 (https=)
JP (1) JP2003507342A (https=)
KR (1) KR20020018201A (https=)
CN (1) CN1229142C (https=)
AR (1) AR029763A1 (https=)
AT (1) ATE341341T1 (https=)
AU (1) AU783116B2 (https=)
BR (1) BR0013219A (https=)
CA (1) CA2380904C (https=)
CZ (1) CZ2002474A3 (https=)
DE (1) DE60031127T2 (https=)
DK (1) DK1202746T3 (https=)
EA (1) EA006876B1 (https=)
ES (1) ES2272305T3 (https=)
HK (1) HK1042244A1 (https=)
HU (1) HUP0203162A3 (https=)
IL (1) IL147913A0 (https=)
MX (1) MXPA02001448A (https=)
NO (1) NO20020663L (https=)
NZ (1) NZ517120A (https=)
PL (1) PL353267A1 (https=)
PT (1) PT1202746E (https=)
WO (1) WO2001012227A1 (https=)
ZA (1) ZA200201156B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
CN1190197C (zh) * 2000-03-13 2005-02-23 惠氏控股公司 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
WO2003008409A1 (en) 2001-07-16 2003-01-30 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ 4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2837227C (en) * 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135900A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
BR9814116A (pt) * 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico

Similar Documents

Publication Publication Date Title
JP2003507342A5 (https=)
JP2008515913A5 (https=)
RU2001131356A (ru) Замещенные 3-циано-[1.7], [1.5] и [1.8] нафтиридиновые ингибиторы тирозинкиназ
EP1202746B1 (en) Nsaid and egfr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
JP2001515071A5 (https=)
CA2299632A1 (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
RU2002117422A (ru) 4-пиримидинил-N-ацил-L-фенилаланины
AR035002A1 (es) 3-cianoquinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
RU2006106267A (ru) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
RU2004110725A (ru) Гетероциклические производные арилзамещенных пиридинов, использование их в качестве блокаторов натриевых каналов, фармацевтическая композиция
JP2019507179A5 (https=)
RU2003114740A (ru) Азотсодержащие ароматические производные
RU2008138649A (ru) Применение а1-агонистов аденозина и/или двойных а1/а2в-агонистов аденозина для получения лекарственных средств для лечения заболеваний
RU2004119414A (ru) 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
RU99104798A (ru) Фармацевтическое средство, содержащее ингибитор rho-киназы
JP2001512103A5 (https=)
WO2006042100A2 (en) Method for the treatment of polycystic kidney disease
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
RU2005103618A (ru) Ингибирующие циклооксигеназу-2 (цог-2) производные пиридина
JP2005503435A5 (https=)
RU2001135802A (ru) Антагонисты рецептора брадикинина
US8148381B2 (en) Potentiator of radiation therapy
EP2370079A2 (en) Hsp90 inhibitors for therapeutic treatment
RU2001114188A (ru) Производные хроменона и хроманона в качестве ингибиторов интегринов